J.P. Morgan Rates CVS Caremark As Overweight

According to J.P. Morgan, CVS Caremark (NYSE: CVS) is rated Overweight.

J.P. Morgan said that, as part of CVS Caremark Week, it discusses takeaways from its conference call yesterday with Larry Merlo, CEO of CVS Caremark. “While nothing materially incremental came out of the call, we found Mr. Merlo's perspectives insightful, in particular, his comments around the integrated offering, the FEP contract decision, industry pricing, and PBM streamlining initiatives.”

CVS Caremark closed yesterday at $37.51.